Exagen Inc. Stock Price, News & Analysis

Exagen Inc. (Nasdaq: XGN) has partnered with Brigham and Women’s Hospital to study the incidence and risk factors of rheumatic autoimmune diseases in COVID-19 survivors. The year-long study will involve positive PCR-confirmed COVID-19 patients categorized by disease severity. Participants will complete questionnaires and undergo testing with AVISE® biomarkers to assess new rheumatic disease symptoms and autoantibody formation. This research aims to clarify the association between COVID-19 recovery and autoimmune disease development, addressing current knowledge gaps in this area.

Exagen Inc. (Nasdaq: XGN) will announce its financial results for the quarter ending September 30, 2020, on November 10, 2020, after market close. The conference call, led by CEO Ron Rocca and CFO Kamal Adawi, will begin at 4:30 PM ET. Investors can join the call by dialing (877) 407-3982 or via webcast on the Exagen investor relations website. A replay will be accessible until November 17, 2020. Exagen focuses on enhancing care for patients with autoimmune diseases through innovative testing products under its AVISE® brand.

Exagen Inc. (XGN) announced participation in the ACR Convergence 2020, a virtual meeting scheduled from November 5-9, where its research on autoimmune diseases, specifically lupus, will be presented. Chief Scientific Officer Anja Kammesheidt emphasized their commitment to advancing understanding of cell-bound complement activation products (CB-CAPs). Several abstracts have been accepted for presentation, showcasing innovative testing products under the AVISE® brand. This event is anticipated to enhance awareness and adoption of Exagen's diagnostics.

Exagen Inc. (Nasdaq: XGN) announced a study published in ACR Open Rheumatology, assessing the economic benefits of AVISE® Lupus testing for systemic lupus erythematosus (SLE). This is the first evaluation comparing AVISE® Lupus with standard diagnostic tests among 1,000 suspected SLE patients, revealing total direct cost savings of $1,991,152, or approximately $1,991 per patient over four years. Year one savings stood at $655,403. The study underscores the importance of early diagnosis in improving patient outcomes and reducing costs for health plans.

Exagen Inc. (Nasdaq: XGN) has announced a partnership with Provider Network of America (PNOA), providing in-network access to over 8 million members for its AVISE® tests designed for autoimmune diseases like rheumatoid arthritis and lupus. PNOA, with contracts across 526 payers and access to 375,000 physicians, aims to enhance diagnostic accuracy and patient care. The partnership is seen as a major step in Exagen's reimbursement strategy, promoting widespread adoption of AVISE® testing and potentially improving outcomes for patients suffering from autoimmune conditions.

Exagen Inc. (Nasdaq: XGN) has announced a preferred provider network agreement with Provider Network of America (PNOA), allowing over 8 million PNOA members in the U.S. to access Exagen's AVISE® tests for autoimmune disorders like rheumatoid arthritis and lupus. This partnership aims to enhance the timely diagnosis and treatment of these conditions, which often take years to diagnose accurately. The agreement is expected to support Exagen's reimbursement strategy and promote broader adoption of its testing products within the healthcare industry.

Exagen Inc. (Nasdaq: XGN) announced the appointment of Wendy S. Johnson as an independent member to its Board of Directors, effective October 1, 2020. Ms. Johnson, who will also serve on the Audit Committee, brings significant healthcare industry experience, including her role as COO at Reneo Pharmaceuticals. This strategic addition aims to support Exagen's growth strategy and enhance its patient-focused culture, reinforcing its commitment to improving care for patients with autoimmune diseases.

Exagen Inc. (Nasdaq: XGN) has launched the AVISE^® Vasculitis AAV testing panel, aimed at improving the diagnosis and monitoring of ANCA-associated vasculitis (AAV). This test enhances Exagen’s AVISE^® portfolio, designed to provide rapid results vital for patient care in autoimmune diseases. As stated by CEO Ron Rocca, this initiative aligns with Exagen's commitment to meet high unmet needs in the rheumatology field. The introduction of this new product underscores the company’s strategy to expand its diagnostic offerings and serve rheumatologists more effectively.

Exagen Inc. (Nasdaq: XGN) announced its participation in the Cantor Fitzgerald Virtual Global Healthcare Conference from September 15-17, 2020. Ron Rocca, President and CEO, will speak in a fireside chat on September 15 at 2:40 pm EDT. Investors can access a live webcast of the event through Exagen's investor relations page, with a replay available for 90 days post-event. Exagen focuses on transforming care for patients with autoimmune diseases, offering innovative testing products under the AVISE® brand to enhance differential diagnosis and therapeutic intervention.